211 related articles for article (PubMed ID: 26409607)
1. Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom.
Bermingham SL; Hughes R; Fenu E; Sawyer LM; Boxall E; T Kennedy P; Dusheiko G; Hill-Cawthorne G; Thomas H
Value Health; 2015 Sep; 18(6):800-9. PubMed ID: 26409607
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness and Clinical Impact of Antiviral Strategies of HBeAg-Positive and -Negative Chronic Hepatitis B.
Oyagüez I; Buti M; Brosa M; Rueda M; Casado MA
Ann Hepatol; 2017; 16(3):358-365. PubMed ID: 28425405
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada.
Tian F; Houle SKD; Alsabbagh MW; Wong WWL
Pharmacoeconomics; 2020 Feb; 38(2):181-192. PubMed ID: 31691902
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China.
Lai K; Zhang C; Ke W; Gao Y; Zhou S; Liu L; Yang Y
Clin Drug Investig; 2017 Mar; 37(3):233-247. PubMed ID: 27928739
[TBL] [Abstract][Full Text] [Related]
5. A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand.
Tantai N; Chaikledkaew U; Tanwandee T; Werayingyong P; Teerawattananon Y
BMC Health Serv Res; 2014 Apr; 14():170. PubMed ID: 24731689
[TBL] [Abstract][Full Text] [Related]
6. First line nucleos(t)ide analog monotherapy is more cost-effective than combination strategies in hepatitis B e antigen-positive chronic hepatitis B patients in China.
Yin XR; Liu ZH; Liu J; Liu YY; Xie L; Tao LB; Jia JD; Cui FQ; Zhuang GH; Hou JL
Chin Med J (Engl); 2019 Oct; 132(19):2315-2324. PubMed ID: 31567376
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of first-line treatment for chronic hepatitis B in China.
Dai Z; Wong IOL; Xie C; Xu W; Xiang Y; Peng L; Lau EHY
Clin Microbiol Infect; 2022 Feb; 28(2):300.e1-300.e8. PubMed ID: 34197929
[TBL] [Abstract][Full Text] [Related]
8. Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy.
Ruggeri M; Basile M; Coretti S; Drago C; Cicchetti A
Appl Health Econ Health Policy; 2017 Aug; 15(4):479-490. PubMed ID: 28197805
[TBL] [Abstract][Full Text] [Related]
9. [Cost-effectiveness of community-based treatment of chronic hepatitis B in China].
Zhang SX; Yang PC; Cai YL; Lin Y; Zou YH
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):860-867. PubMed ID: 28738456
[No Abstract] [Full Text] [Related]
10. Cost-effectiveness of testing hepatitis B-positive pregnant women for hepatitis B e antigen or viral load.
Fan L; Owusu-Edusei K; Schillie SF; Murphy TV
Obstet Gynecol; 2014 May; 123(5):929-937. PubMed ID: 24785842
[TBL] [Abstract][Full Text] [Related]
11. Effects of IFN monotherapy versus combined therapy on HBeAg seroconversion or seroclearance in HBeAg-positive chronic hepatitis B patients: A meta-analysis.
Zhu F; Zhang Q; Zhang Q; Zhang D
Microb Pathog; 2020 Feb; 139():103912. PubMed ID: 31816402
[TBL] [Abstract][Full Text] [Related]
12. Albumin-bilirubin score is associated with response to pegylated interferon and nucleos(t)ide analogues in chronic hepatitis B patients.
Xun Z; Liu C; Yu QQ; Lin JP; Huang JL; Yang TW; Wu WN; Wu SH; Ou QS
Clin Chim Acta; 2020 Mar; 502():120-127. PubMed ID: 31891671
[TBL] [Abstract][Full Text] [Related]
13. A comparative network meta-analysis of standard of care treatments in treatment-naïve chronic hepatitis B patients.
Sbarigia U; Vincken T; Wigfield P; Hashim M; Heeg B; Postma M
J Comp Eff Res; 2020 Oct; 9(15):1051-1065. PubMed ID: 32945178
[No Abstract] [Full Text] [Related]
14. Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials.
Wong WWL; Pechivanoglou P; Wong J; Bielecki JM; Haines A; Erman A; Saeed Y; Phoon A; Tadrous M; Younis M; Rayad NZ; Rac V; Janssen HLA; Krahn MD
Syst Rev; 2019 Aug; 8(1):207. PubMed ID: 31426837
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B.
Kim HL; Kim GA; Park JA; Kang HR; Lee EK; Lim YS
Gut; 2021 Nov; 70(11):2172-2182. PubMed ID: 33239344
[TBL] [Abstract][Full Text] [Related]
16. A Cost-Utility and Cost-Effectiveness Analysis of Different Oral Antiviral Medications in Patients With HBeAg-Negative Chronic Hepatitis B in Iran: An Economic Microsimulation Decision Model.
Keshavarz K; Kebriaeezadeh A; Alavian SM; Akbari Sari A; Rezaei Hemami M; Lotfi F; Hashemi Meshkini A; Javanbakht M; Keshvari M; Nikfar S
Hepat Mon; 2016 Sep; 16(9):e37435. PubMed ID: 27822262
[TBL] [Abstract][Full Text] [Related]
17. Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort.
Ruggeri M; Coretti S; Romano F; Kondili LA; Vella S; Cicchetti A
Value Health; 2018 Jul; 21(7):783-791. PubMed ID: 30005750
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus.
Fawsitt CG; Vickerman P; Cooke GS; ; Welton NJ
Value Health; 2020 Feb; 23(2):180-190. PubMed ID: 32113623
[TBL] [Abstract][Full Text] [Related]
19. The Effectiveness of Antiviral Treatments for Patients with HBeAg-Positive Chronic Hepatitis B: A Bayesian Network Analysis.
Hao Z; Biqing Z; Ling Y; Wenting Z
Can J Gastroenterol Hepatol; 2018; 2018():3576265. PubMed ID: 30276197
[TBL] [Abstract][Full Text] [Related]
20. Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis.
Ciaccio A; Cortesi PA; Bellelli G; Rota M; Conti S; Okolicsanyi S; Rota M; Cesana G; Mantovani LG; Annoni G; Strazzabosco M
Liver Int; 2017 Jul; 37(7):982-994. PubMed ID: 27943549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
